Ligand Announces Favorable Results From Phase 1b Trial With LGD-6972 in Type 2 Diabetes and Plans to Initiate a Phase 2 Trial
Ligand Announces New Time for June 7th Investor Presentation and Webcast at the American Diabetes Association 75th Scientific Sessions
Ligand Summarizes the Accounting Impact of the Viking Therapeutics, Inc. IPO and Updates 2015 Financial Guidance
Ligand Reports First Quarter 2015 Financial Results
Ligand Acquires Rights to More Than 15 Fully-Funded Development Programs from Selexis SA
Ligand to Present Results of LGD-6972 Phase 1b Trial at American Diabetes Association 75th Scientific Sessions on June 7th and Host Investor Presentation
Ligand Partner Viking Therapeutics Announces Closing of Initial Public Offering
Ligand Partner Viking Therapeutics Announces Pricing of Initial Public Offering
Ligand to Participate in Two Upcoming Investor Conferences
Ligand to Report First Quarter Results on May 11th
Ligand Names Melanie J. Herman Interim Chief Financial Officer
Ligand Earns Milestone from SAGE Therapeutics for SAGE-547
Ligand Partner TG Therapeutics Presents Positive Pre-clinical Data on IRAK4 Compounds at the American Association for Cancer Research (AACR) Annual Meeting
Ligand to Present at the 27th Annual Roth Conference on March 9th
